Skip to main content
Explore URMC
menu

Gastric or Gastroesophageal Junction: Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)

Research Question:
What is the safety, efficacy, and tolerability of the research study drug pembrolizumab (MK-3475) in combination with cisplatin and capecitabine or cisplatin and 5-fluorouracil (5-FU) or FLOT (docetaxel, oxaliplatin, 5-FU and leucovorin)?

Basic Study Information

Purpose:
If you decide to participate in this research study, your study doctor will assign you to one of three chemotherapy treatments: XP (cisplatin and capecitabine), FP (cisplatin and 5-FU) or FLOT (docetaxel, oxaliplatin, 5-FU and leucovorin). Once you are assigned a chemotherapy treatment, you will be assigned by chance to receive either chemotherapy + pembrolizumab before and after surgery followed by pembrolizumab only or chemotherapy + placebo (look-alike with no active ingredients) before and after surgery followed by placebo only. You may still be able to continue in the study if you are unable to have or no longer need surgery. The study doctor will discuss this with you. You will be assigned by chance to get either pembrolizumab or placebo (a look alike with no active ingredients). You have a 1 in 2 chance of getting placebo only. Neither you nor the study doctor will know if you are receiving pembrolizumab or placebo.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT03221426?term=KEYNOTE-585&rank=1
Study Reference #: IGIE17066

Lead Researcher (Principal Investigator)

Lead Researcher: Mohamedtaki Tejani, MD

Study Contact Information

Study Coordinator: Chris Le Feber
Phone: (585) 275-0407
Email: Chris_LeFeber@URMC.Rochester.edu

Additional Study Details

Return to Search